FDA Bioequivalence Standards / edited by Lawrence X. Yu, Bing V. Li.
By: Yu, Lawrence X., editor literario
Contributor(s): Li, Bing V., editor literario
Material type:
E-bookSeries: (AAPS Advances in the Pharmaceutical Sciences Series, 2210-7371; 13).Publisher: New York : Springer International Publishing, 2014Description: 1 recurso en línea (XIII, 465 páginas) : 58 ilustraciones, 26 ilustraciones en color.ISBN: 9781493912520.Subject: Tecnología farmacéutica
| Item type | Current library | Collection | Call number | Copy number | Status | Date due | Barcode | Item holds | |
|---|---|---|---|---|---|---|---|---|---|
LIBRO-E NO PRÉSTAMO
|
Madrid Digital Acceso Electrónico (UEM) | Ciencias de la Salud | RM301.45 Y853 2014 EB (Browse shelf(Opens below)) | .i11546992 | Acceso electrónico | eBOOK .i11546992 |
Browsing Madrid Digital shelves, Shelving location: Acceso Electrónico (UEM) Close shelf browser (Hides shelf browser)
| RM301.41 C666 2006 EB Insights into Receptor Function and New Drug Development Targets | RM301.41 S546 2017 EB Sigma receptors : their role in disease and as therapeutic targets | RM301.45 .K36 2017 EB Bioequivalence requirements in various global jurisdictions | RM301.45 Y853 2014 EB FDA Bioequivalence Standards | RM301.5 2020 EB Circadian Pharmacokinetics | RM301.5 2021 EB Quantitative Analysis of Cellular Drug Transport, Disposition, and Delivery | RM301.5 2022 EB The ADME Encyclopedia . A Comprehensive Guide on Biopharmacy and Pharmacokinetics |
1 Bioequivalence History -- 2 Fundamentals of Bioequivalence -- 3 Basic Statistical Considerations -- 4 The Effects of Food on Drug Bioavailability and Bioequivalence -- 5 Bio waiver and Biopharmaceutics Classification System -- 6 Bioequivalence of Highly Variable Drugs -- 7 Partial Area under the Curve: An Additional Pharmacokinetic Metric for Bioavailability and Bioequivalence Assessments -- 8 Bioequivalence for Narrow Therapeutic Index Drugs -- 9 Pharmacodynamic Endpoint-based Bioequivalence Studies -- 10 Clinical Endpoint Bioequivalence Study -- 11 Bioequivalence for Liposomal Drug Products -- 12 Bioequivalence for Drug Products Acting Locally within Gastrointestinal Tract -- 13 Bioequivalence for Topical Drug Products -- 14 Bioequivalence for Orally Inhaled and Nasal Drug Products -- 15 Bioequivalence: Modeling and Simulation -- 16 Bioanalysis.
This comprehensive reference provides an in-depth discussion on state-of-the-art regulatory science in bioequivalence. In sixteen chapters, the volume explores a broad range of topics pertaining to bioequivalence, including its origin and principles, statistical considerations, food effect studies, conditions for waivers of bioequivalence studies, Biopharmaceutics Classification Systems, Biopharmaceutics Drug Disposition Classification System, bioequivalence modeling/simulation, and best practices in bioanalysis. It also discusses bioequivalence studies with pharmacodynamic and clinical endpoints as well as bioequivalence approaches for highly variable drugs, narrow therapeutic index drugs, liposomes, locally acting gastrointestinal drug products, topical products, and nasal and inhalation products. FDA Bioequivalence Standards is written by FDA regulatory scientists who develop regulatory policies and conduct regulatory assessment of bioequivalence. As such, both practical case studies and fundamental science are highlighted in these chapters. The book is a valuable resource for scientists who work in the pharmaceutical industry, regulatory agencies, and academia as well as undergraduate and graduate students looking to expand their knowledge about bioequivalence standards.
There are no comments on this title.